Allt inom mfn-ext-nq-company-announcement

Nanexa Receives Approval for Late Breaking Abstract at ADA Congress in Chicago in June

Nanexa announces that the results from the recently completed Phase I-study with NEX-22 have been approved as a Late Breaking Abstract at the prestigious ADA Congress (American Diabetes Association) held in Chicago June 20-23.

Nanexa and Applied Materials terminates collaboration

Nanexa and Applied Materials, Inc. have collaborated since 2020 regarding production equipment to be used for upscaling of the PharmaShell process. The companies have now agreed to terminate the collaboration.